The landmark Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT®) was a global outcomes study designed to assess the cardioprotective efficacy and safety of VASCEPA® (icosapent ethyl) as an add-on to statin therapy in reducing major cardiovascular (CV) events in a high-risk patient population. Join endocrine experts Eliot A. Brinton, MD, FAHA, FNLA, FACE, President of Utah Lipid Center, and Past President, of the American Board of Clinical Lipidology, and Betul Hatipoglu MD, Professor of Medicine at CWRU School of Medicine, and Medical Director for Diabetes & Obesity Center at University Hospital Cleveland Medical Center, to learn about the results of the REDUCE-IT® trial and new developments in CV prevention.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related